Laboratory of Hematology-Oncology and Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy.
Drug Discov Today. 2011 Dec;16(23-24):1052-60. doi: 10.1016/j.drudis.2011.08.007. Epub 2011 Aug 22.
The anti-angiogenic class of drugs is one of the few where representatives have gained international approval for clinical use in oncology during the past decade. Most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets vascular endothelial growth factor (VEGF) and its related pathways. However, the clinical benefits associated with the use of these drugs have, so far, been limited. There is, therefore, an unmet need for biomarkers that can be used to identify patients who are most likely to benefit therapeutically and also to predict the best schedule and dosage for these drugs. Here, we discuss some of the emerging new combination strategies involving the approved anti-angiogenic drugs, some of the emerging targets associated with neoplastic angiogenesis and some novel agents used as a paradigm of the next generation of anti-angiogenic drugs.
抗血管生成药物是过去十年中少数几种在肿瘤学临床应用方面获得国际认可的药物之一。目前可用的抗血管生成药物的大多数生物学和临床活性都针对血管内皮生长因子（VEGF）及其相关途径。然而，到目前为止，这些药物的临床获益是有限的。因此，需要有生物标志物来识别最有可能从治疗中获益的患者，也需要预测这些药物的最佳方案和剂量。在这里，我们讨论了一些涉及已批准的抗血管生成药物的新兴联合策略，一些与肿瘤血管生成相关的新兴靶点，以及一些作为下一代抗血管生成药物范例的新型药物。
